PTEN deletion is an established prognostic biomarker in prostate cancer. We compared
PTEN immunohistochemistry (IHC) and PTEN fluorescence in situ hybridization (FISH) in the …

Understanding the genomic profiling of prostate cancer is crucial, owing to the emergence of
precision medicine to guide therapeutic approaches. Over the last decade, integrative …

Evolution by natural selection is the conceptual foundation for nearly every branch of biology
and increasingly also for biomedicine and medical research. In cancer biology, evolution …

With the advent of next-generation sequencing technologies and large whole-exome and
genome studies in prostate and other cancers, our understanding of the landscape of …

Background Genomic copy number alterations commonly occur in prostate cancer and are
one measure of genomic instability. The clinical implication of copy number change in …

Purpose This study investigates the diagnostic and prognostic biomarker potential of
miRNAs in prostate cancer (PC). Results We identified several new deregulated miRNAs …

To study genetic factors influencing the progression and therapeutic responses of advanced
prostate cancer, we developed a fast and flexible system that introduces genetic alterations …

Background Gastric cancer (GC) is confronted with limited options for precision medicine.
Human epidermal growth factor receptor 2 (HER2) is the principal druggable target of GC …

The identification of new biomarkers to differentiate between indolent and aggressive
prostate tumors is an important unmet need. We examined the role of THOR (TERT …

Prostate cancer (PCa) is a non-cutaneous malignancy in males with wide variation in
incidence rates across the globe. It is the second most reported cause of cancer death. Its …